文献速递心力衰竭与心肌病

KCCQ-12与KCCQ-23在HFmrEF/HFpEF患者中的可互换性

Interchangeability of the KCCQ-12 and KCCQ-23 Across >18,000 Participants Enrolled in 4 Large-Scale Trials of Heart Failure.
PubMed 文献 · J Am Coll Cardiol · 2026-03-16

结果显示两种量表评分高度相关,对心血管死亡和心衰住院的预后区分能力相当,药物治疗效果评估结果相似。KCCQ-12可作为降低患者负担的替代工具用于心衰临床试验。

要点

  • KCCQ-12与KCCQ-23在HFmrEF/HFpEF患者中高度相关,评分差异小。
  • 两种量表对心血管死亡和心衰住院的预后区分能力相当。
  • KCCQ-12可降低受试者填写负担,适用于心衰临床试验。

核心结论

  • 在HFmrEF/HFpEF患者中,KCCQ-12与KCCQ-23高度一致,预后区分能力和治疗反应性评估表现相当,支持KCCQ-12作为低负担替代工具用于心衰临床试验。

研究设计与样本

  • 基线人群特征:年龄72±9岁,女性46%,NYHA心功能II级72%,平均LVEF为55±8%,中位NT-proBNP为987(IQR:517-1781)pg/mL。

主要发现

  • 基线KCCQ-23 OSS为65.5±21.4,KCCQ-12 OSS为64.1±21.7,两者Spearman相关系数为0.987,各主要亚组及随访时点相关系数均大于0.980。
  • 对心血管死亡和心衰住院的预后区分C指数:KCCQ-23为0.583,KCCQ-12为0.586,结果相当。
  • 每项试验及每个时间点两种量表评估心衰药物治疗效果的总分差异均小于1分(0-100分标度)。

关键数值与推荐

  • KCCQ-12 OSS与KCCQ-23 OSS基线Spearman相关系数为0.987,各亚组及随访时点相关系数均大于0.980。
  • 预后区分C指数:KCCQ-23为0.583,KCCQ-12为0.586。
  • 两种量表评估治疗效果的差异均小于1分(0-100分标度)。

临床怎么用

  • 对于HFmrEF/HFpEF患者,KCCQ-12可替代KCCQ-23用于评估健康相关生活质量,降低填写负担。
  • KCCQ-12可用于心衰临床试验中的预后分层和治疗效果评估。

局限性

  • KCCQ-12评分由KCCQ-23的项目直接推导而来,并非独立填写KCCQ-12量表。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The 23-item Kansas City Cardiomyopathy Questionnaire (KCCQ-23) is formally qualified by the Food and Drug Administration as a valid patient-reported outcome measure for use in heart failure (HF) clinical trials. However, its length may increase respondent burden. The 12-item version (KCCQ-12) provides a more efficient alternative but was originally developed and validated in HF with reduced left ventricular ejection fraction (LVEF), and its performance relative to the KCCQ-23 has not been evaluated in HF with mildly reduced or preserved LVEF (HFmrEF/HFpEF). OBJECTIVE: The purpose of this study is to examine the interchangeability of KCCQ-12 and KCCQ-23 in patients with HFmrEF/HFpEF. METHODS: We conducted a participant-level pooled analysis of 4 randomized clinical trials (TOPCAT, PARAGON-HF, DELIVER, and FINEARTS-HF), including adults with HFmrEF/HFpEF. All trials collected the KCCQ-23 at baseline and follow-up visits. In this study, the KCCQ-12 overall summary scores (OSS) were derived from individual items of the KCCQ-23 OSS. Both scores ranged from 0 (worst) to 100 (best). We assessed concordance between KCCQ-12 OSS and KCCQ-23 OSS and compared prognostic discrimination and treatment-related changes. RESULTS: Of 18,216 participants (mean age: 72 ± 9 years; female: 46%; NYHA functional class II: 72%; mean LVEF: 55 ± 8%; median N-terminal pro-B-type natriuretic peptide levels: 987 [IQR: 517-1,781] pg/mL), baseline KCCQ-23 OSS was 65.5 ± 21.4, and KCCQ-12 OSS was 64.1 ± 21.7. Baseline KCCQ-12 OSS strongly correlated with KCCQ-23 OSS (Spearman ρ = 0.987), consistent across major subgroups and follow-up visits (all Spearman ρ > 0.980). Prognostic discrimination for cardiovascular death and HF hospitalization was comparable (C index: 0.583 for KCCQ-23 vs 0.586 for KCCQ-12). Treatment effects of HF drugs on KCCQ-OSS were similar across the 2 instruments in each trial and at each time point (all the differences between KCCQ-23 and KCCQ-12 were <1 point on a 0-100 scale). CONCLUSIONS: In patients with HFmrEF/HFpEF, the KCCQ-12 closely parallels the KCCQ-23, demonstrating comparable prognostic performance and treatment responsiveness. These findings support the KCCQ-12 as a lower-burden alternative for use in HF clinical trials. (Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist; NCT00094302; Prospective Comparison of Angiotensin Receptor-Neprilysin Inhibitor with Angiotensin Receptor Blocker Global Outcomes in HF with Preserved Ejection Fraction; NCT01920711; Dapagliflozin Evaluation to Improve the Lives of Patients With Preserved Ejection Fraction Heart Failure; NCT03619213; Finerenone Trial to Investigate Efficacy and Safety Superior to Placebo in Patients with Heart Failure; NCT04435626).

来源:J Am Coll Cardiol,查看原文。版权归原作者所有。

引用

  1. Hamatani, Claggett, Desai, et al. Interchangeability of the KCCQ-12 and KCCQ-23 Across >18,000 Participants Enrolled in 4 Large-Scale Trials of Heart Failure. J Am Coll Cardiol. 2026. PMID: 41995644. doi:10.1016/j.jacc.2026.03.026

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。